PE-22-28 10mg

Description

PE-22-28 is a shortened synthetic analog of the naturally occurring peptide spadin, designed to potently block the TREK-1 potassium channel. By antagonizing TREK-1, PE-22-28 promotes rapid neurogenesis, exhibits antidepressant-like effects within days, and supports research into mood regulation, stroke recovery, and neurodegenerative disease models.

Sequence & Composition

• Amino Acid Sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg (GVSWGLR)

• Molecular Formula: C₃₅H₅₅N₁₁O₉

• Molecular Weight: 773.9 Da

Research & Applications

• Antidepressant Activity: Rapidly reverses depressive-like behaviors in rodent models without affecting other TREK-1–regulated functions.

• Neurogenesis: Doubles hippocampal BrdU-positive cell counts within four days, indicating accelerated neuronal proliferation.

• Stroke Recovery: Reduces apoptotic cell death and improves motor and cognitive outcomes in ischemia models.

• Mechanistic Insights: Modulates CREB activation and supports synaptogenesis, offering a potential nootropic benefit.

Recommended Usage

• In Vitro: 0.1 – 10 µM in cell culture assays.

• In Vivo (Rodent Studies): 0.1 – 1 mg/kg via intraperitoneal or intravenous injection, once daily or per protocol.

• Solubility: Dissolve in sterile water or PBS; gentle warming (~37 °C) may aid dissolution.

Packaging & Storage

• Packaging: 10 mg amber glass vial with desiccant.

• Shelf Life: Up to 12 months unopened.

• Storage Conditions: 2 – 8 °C; protect from light and moisture; avoid repeated freeze–thaw cycles.

For laboratory research use only. Not for human or veterinary consumption.

References

1. R&D Systems – PE-22-28 Product Data Sheet

2. ScienceDirect – “Fighting against depression with TREK-1 blockers”

3. PMC – “Shortened Spadin Analogs Display Better TREK-1 Inhibition”

4. Core research on PE-22-28 neurogenesis and stroke models